Novartis Stock Forecast 2035: Bull, Bear, and Base Case

01. Historical Context

Novartis in context: what kind of long-term stock this has been

At CHF 118.04 on May 15, 2026, Novartis is entering the next decade from a position of strength. The stock's 10-year range of CHF 39.77 to CHF 126.65 and 10-year CAGR of 10.0% already show what a mature pharma compounder can do.

The business case is similarly strong. FY 2025 net sales were USD 54.532 billion, up 8% at constant currencies, and core operating margin was 40.1%. But the Q1 2026 reset matters because it shows how patent cycles can interrupt even a very strong franchise base.

For 2035, that combination matters. Unlike Sanofi, Novartis does not need a rescue rerating. It needs to extend an already solid compounding model into radioligand therapy, xRNA, and the next wave of launches.

2035 bull, bear, and base case for Novartis — Long-term ranges anchored to the current price, 10-year trading history, and the latest verified company and institutional data.

Novartis framework across investor time horizons

Horizon	What matters now	Current datapoint	What would strengthen the thesis
1-3 months	Execution versus guidance	Q1 2026 net sales were USD 13.1 billion, down 5% at constant currencies, while core EPS was USD 1.99, down 15% at constant currencies.	Management keeps 2026 guidance and brand-level momentum remains intact.
6-18 months	Valuation versus revisions	MarketScreener showed Novartis at about 19.2x trailing 2025 earnings, 20.1x 2026 estimated earnings, and 17.3x 2027 estimated earnings. Consensus EPS on MarketScreener was USD 7.244 for 2026 and USD 8.433 for 2027, implying roughly 16.4% growth into 2027.	Consensus EPS moves higher while the multiple does not need to do all the work.
To 2035	Structural compounding	10-year price range CHF 39.77 to CHF 126.65; 10-year CAGR 10.0%.	The company sustains growth through launches, pipeline conversion, and disciplined capital allocation.

02. Key Forces

Five forces that will shape the path to 2035

The first force is whether the 2025-2030 growth algorithm survives contact with reality. Management's 5% to 6% sales CAGR target is the single most useful long-term anchor.

The second force is whether the platform mix expands. Novartis is explicitly prioritizing chemistry, biotherapeutics, gene and cell therapy, radioligand therapy, and xRNA.

The third force is whether the US investment program translates into faster scale. The USD 23 billion footprint expansion is large enough to matter if those platforms keep growing.

The fourth force is capital returns. Novartis has shown it can invest heavily and still repurchase stock, which matters a lot over a 10-year horizon.

The fifth force is valuation discipline. A stock that already trades near 20x forward earnings can still outperform, but more of the return has to come from the business itself.

Current factor scorecard for Novartis

Factor	Current Assessment	Bias	Why it matters now
Growth algorithm	5% to 6% sales CAGR through 2030	Bullish	This is the cleanest starting point for a 2035 model.
Platform expansion	Radioligand, xRNA, gene and cell therapy remain priority investments	Bullish	The company is trying to widen its future cash-flow base.
Manufacturing scale	USD 23 billion US plan with seven new facilities announced within a year	Bullish	That spending supports future launches and supply resilience.
Starting valuation	About 20.1x 2026 EPS	Neutral	Great business, but not a bargain multiple.
Erosion cycle	Q1 2026 still pressured by US generic erosion	Neutral to Bearish	The long-term thesis is stronger if 2026 proves temporary.

03. Countercase

What would break the long-term case

The main long-term risk is that Novartis becomes a good business but a mediocre stock because too much of the future return is already priced in.

A second risk is that platform spending stays heavy while product replacement is slower than expected. That would pressure margins and weaken the 2030-to-2035 compounding arc.

A third risk is policy and reimbursement pressure, especially in the US. The December 2025 government agreement reduced one uncertainty but does not remove the sector's pricing sensitivity.

A fourth risk is broader market opportunity cost. If the S&P 500 keeps a high forward multiple while healthcare remains an earnings laggard, investors may continue to treat defensive pharma as a funding source rather than a destination.

2035 risk map

Risk	Latest datapoint	Current assessment	Bias
Already-recognized quality	Hold consensus and mid-single-digit ADR upside on MarketScreener	Real valuation constraint	Neutral to Bearish
Heavy investment cycle	Large platform and manufacturing buildout underway	Worth it only if growth follows	Neutral
Policy pricing risk	US agreement helps, but the sector stays sensitive	Persistent overhang	Neutral
Sector opportunity cost	FactSet still shows healthcare lagging earnings breadth	Can suppress multiples	Neutral

04. Institutional Lens

How institutional inputs help frame the decade view

The IMF, FactSet, and J.P. Morgan are useful here for different reasons. The IMF says growth remains positive but fragile. FactSet says healthcare is still lagging on breadth. J.P. Morgan says healthcare multiples remain unusually compressed versus the S&P 500.

For Novartis, that combination means relative downside can be limited if investors want quality, but the upside still has to come from operating proof rather than macro enthusiasm.

Sell-side data fit that interpretation. On May 7, 2026, MarketScreener listed 22 analysts on the Novartis ADR with a Hold consensus, average target USD 155.06, low target USD 121.07, and high target USD 178.42. The market respects Novartis, but it is not treating the stock as obviously mispriced.

Named institutional inputs used in this article

Source	Latest update	What it says	Why it matters here
MarketScreener, May 7, 2026	On May 7, 2026, MarketScreener listed 22 analysts on the Novartis ADR with a Hold consensus, average target USD 155.06, low target USD 121.07, and high target USD 178.42.	Analysts see only modest upside on the ADR, which implies the market already gives meaningful credit to quality and capital returns.	That makes execution on priority brands and generic erosion the main swing factors.
IMF, April 2026	Global growth 3.1% in 2026 and 3.2% in 2027.	The IMF said downside risks still dominate because of conflict, fragmentation, and disappointment over AI productivity.	A slower macro tape usually limits multiple expansion for defensive growth names as well as cyclical names.
FactSet, May 1, 2026	Health Care was one of only two S&P 500 sectors reporting a year-over-year earnings decline; the S&P 500 forward P/E was 20.9x.	FactSet's message is that broad equity valuations are not cheap even as healthcare revisions remain mixed.	That raises the bar for stock-specific execution and makes relative valuation important.
J.P. Morgan Asset Management, 2026	Public healthcare multiples sit at 30-year lows relative to the S&P 500 despite USD 318 billion of M&A across 2,500-plus transactions in 2025.	J.P. Morgan's sector view is that policy noise has compressed healthcare valuations relative to the market.	That helps explain why solid pharma execution can still re-rate if policy fears fade.

05. Scenarios

Bull, base, and bear paths with explicit review dates

The base case below assumes Novartis keeps compounding from a higher-quality starting point than Sanofi but without a huge multiple expansion kicker.

Investors should revisit the thesis after FY 2026, after the 2025-2030 growth bridge is tested for two or three years, and again once the large US platform buildout is far enough along to measure returns rather than promises.

2035 scenario map for Novartis

Scenario	Probability	Target range	Trigger	When to review
Bull case	20%	CHF 220 to CHF 280	The 5% to 6% sales CAGR is sustained, newer platforms scale, and margins remain at or above the long-term 40% level.	Review annually and after major platform milestones.
Base case	55%	CHF 160 to CHF 210	The business compounds steadily and most of the return comes from earnings growth, dividends, and modest buyback support.	Review after FY 2026 and then every 12 months.
Bear case	25%	CHF 110 to CHF 150	Generic erosion, pricing pressure, or heavy investment keep returns below the quality premium already embedded in the stock.	Review if long-term growth guidance is cut.